CARDIOPROGRESS
Foundation for the advancement of cardiology

Time-Restricted Eating May Help Adults With Metabolic Syndrome Improve Several Health Markers According to a randomized controlled trial, adults with metabolic syndrome and elevated blood sugar levels who eat for a limited time may experience minor improvements in several indicators, including A1c levels, weight, and body fat.

Impact of multiple obesity metrics on hypertensive disorders of pregnancy: a meta-analysis and Mendelian randomisation study This study demonstrates that various obesity measures are causally linked to increased HDP risk and highlights the mediating role of triglycerides. These findings could inform clinical practices and public health strategies aimed at reducing HDP through targeted obesity and triglyceride management.

Optimal treatment of symptomatic patients with low-gradient severe Aortic valve Stenosis and preserved left ventricular ejection fraction (ROTAS trial) The best management of symptomatic patients with low-gradient (LG) severe aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF) has not been established.

Cardiovascular safety of vitamin B3 administration Scientists recently reported associations between serum levels of the terminal niacin metabolites N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY) with an increased 3-year incident risk of major adverse cardiovascular events.

Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function Semaglutide (Wegovy) prevents major cardiac events including death in adults with overweight/obesity and cardiovascular disease (CVD), both with and without impaired kidney function, a subgroup analysis of the Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) trial shows.

Persistence of residual shunt at 6 and 12 months after transoesophageal echocardiography-guided percutaneous closure of a patent foramen ovale for cryptogenic stroke Young patients suffering from cryptogenic stroke alongside a patent foramen ovale (PFO) are often considered for percutaneous device closure to reduce the risk of stroke recurrence. Residual right-to-left shunt after device closure may persist in approximately a quarter of the patients at 6 months, and some may close at a later time point.

Can AI Improve Cardiomyopathy Detection in Pregnant Women? Artificial intelligence (AI)–guided screening using digital stethoscopes doubled the detection of left ventricular systolic dysfunction (LVSD) in pregnant and postpartum women in Nigeria.

Study shows cardiovascular health benefits can begin shortly after quitting smoking Quitting cigarettes can significantly lower a person's risk of atrial fibrillation (AFib) compared to those who continue to smoke, according to a study published in JACC: Clinical Electrophysiology. The findings show that the benefits of quitting start right away, suggesting that it is possible to reverse the risk of negative health outcomes.

Balloon Angioplasty Plus Medical Management for sICAS. Study Adding balloon angioplasty to aggressive medical management significantly lowers the risk for stroke or death in patients with symptomatic intracranial atherosclerotic stenosis (sICAS), results of a new randomized clinical trial showed.

Pilot: OCT Parameter Tracks Atherosclerosis Progression The histopathological status of an atherosclerotic plaque can not only be quantified but also tracked over time by using a parameter calculated from optical coherence tomography (OCT) images, researchers from the Chinese PLA General Hospital in Beijing, China, have found.

Results of the 36th International Congress of Cardiology "Great Wall" and the Asian Congress of Cardiology 2025 The 36th International Congress of Cardiology “Great Wall” and the Asian Congress of Cardiology 2025 took place at the National Exhibition Center in Beijing from October 16 to 19, 2025.

New guidelines may help prevent sudden death in myocarditis The European Society of Cardiology (ESC) recently released its 2025 guidelines for the management of myocarditis, which also includes extensive discussion of pericarditis and the wide range of overlap between these types of cardiac inflammation. The guidelines were presented at the ESC Congress 2025 in Madrid and simultaneously published in the European Heart Journal.

New Insight Into CVD, Stroke Risk in Migraine Researchers are unraveling the complex relationship between cardiovascular (CV)- and stroke-related outcomes in migraine with, and without, aura.

How to Get Published in a Specialized Journal Every month, hundreds of manuscripts land in the inboxes of biomedical journals. For example, researchers submitted more than 2200 articles to JAMA Cardiology in 2023. Only 6% of all original research papers were accepted.

Roche Blood Test for Lp(a) Designated Breakthrough Device A blood test that measures lipoprotein(a) [Lp(a)] has received breakthrough device designation from the US Food and Drug Administration. The Tina-quant Lp(a) RxDx assay, developed by Roche in partnership with Amgen, is designed to identify adults with elevated Lp(a) levels who may benefit from lipid-lowering therapies currently in development.

New TAVI Platform Adds More Valve Sizes to Choose From Intermediate valve sizes are at least as safe and effective as the standard sizes now available for transcatheter aortic valve implantation (TAVI), according to an international randomized trial.

World Red Cross Day and Red Crescent Day World Red Cross Day and Red Crescent Day is celebrated on 8 May every year. This date is the birth anniversary of Henry Dunant, who was born on 8 May 1828 at Geneva, Switzerland, and died on 30 October 1910 at Heiden, Switzerland. He was the founder of (ICRC) International Committee of the Red Cross and the recipient of the first Nobel Peace Prize in 1901.

Lower CVD Risk With Stable DMARD Therapy in Seropositive Rheumatoid Arthritis The risk for cardiovascular diseases (CVDs) is lower in patients with seropositive rheumatoid arthritis (RA) who remain on stable disease-modifying antirheumatic drug (DMARD) therapy than in those whose treatment regimen is not stable.

Novel PCSK9 Inhibitor Reduced LDL by 50% Lerodalcibep, a novel, third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, reduced low-density lipoprotein cholesterol (LDL-C) by more than 50% after 1 year in patients with or at a high risk for cardiovascular disease (CVD), new phase 3 results showed.

ACC/AHA Issue Updated Atrial Fibrillation Guideline The American College of Cardiology (ACC), the American Heart Association (AHA), the American College of Chest Physicians (ACCP), and the Heart Rhythm Society (HRS) have issued an updated guideline for preventing and optimally managing atrial fibrillation (AF).